

Expected R&D Milestones

Pipeline charts as communicated at full-year results meeting dated February 7, 2019

Products	Expected milestones	Timing
Dupixent®	U.S. regulatory decision in Atopic Dermatitis in Adolescent patients	Q1 2019
Zynquista™ (sotagliflozin)	U.S. regulatory decision expected in Type 1 Diabetes	Q1 2019
dupilumab	U.S. sBLA filing in Nasal Polyposis	Q1 2019
Dupixent®	EU regulatory decision in Asthma in Adult/Adolescent patients	Q2 2019
Zynquista™ (sotagliflozin)	EU regulatory decision expected in Type 1 Diabetes	Q2 2019
Praluent®	EU regulatory decision in CV events reduction ODYSSEY OUTCOMES	Q2 2019
Praluent®	U.S. regulatory decision in CV events reduction ODYSSEY OUTCOMES	Q2 2019
cemiplimab	EU regulatory decision expected in Advanced Cutaneous Squamous Cell Carcinoma	Q2 2019
dupilumab	Start of Phase 2b/3 trial in Chronic Obstructive Pulmonary Disease	H1 2019
Dupixent®	EU regulatory decision in Atopic Dermatitis in Adolescent patients	Q3 2019
sutimlimab	Expected pivotal trial read-out in Cold Agglutinin Disease	Q4 2019
Zynquista™ (sotagliflozin)	Expected pivotal trial read-out in Type 2 Diabetes	Q4 2019
Dupixent®	Expected pivotal trial read-out in Atopic Dermatitis in 6-11 years	Q4 2019
olipudase	Expected pivotal trial read-out in Niemann Pick Type B	Q4 2019
isatuximab	Expected pivotal trial read-out in 1-3L RRMM (IKEMA)	Q1 2020